Cynata Announces Ethics Approval and Expedited Regulatory Pathway for Phase 3 Osteoarthritis Clinical Trial

    NEXT STORY
    PRA Health Sciences ready to navigate RACE Act requirements for pediatric oncology
    PREV STORY
    Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

    LA JOLLA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company ...

    author_avatar
    NASDAQ Market News

    OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products

    Key Clinical Portfolio Development Progress Planned for 2018              Tedopi® (neoepitopes): Phase 3 clinical trial in ...

    author_avatar
    NASDAQ Market News

    Point of Care Testing Market will surge at 7%+ CAGR to hit $34.2 billion by 2024: Global Market Insights, Inc.

    author_avatar
    NASDAQ Market News